News | Ventricular Assist Devices (VAD) | January 08, 2016

i-cor Synchronized Cardiac Assist Preserves LV Function in Cardiogenic Shock

Czech study results show device offers less invasive alternative to continuous flow extracorporeal life support

January 8, 2016 — XENiOS announced that its i-COR Synchronized Cardiac Assist system protects left ventricular (LV) function compared to continuous-flow ECLS (extracorporeal life support) in cardiogenic shock.

Study data were presented at the American Heart Association (AHA) annual meeting, Nov. 7-11 in Orlando, Fla., by principal investigator Petr Ošťádal, M.D., Ph.D., Charles University, Na Homolce Hospital, Prague, Czech Republic.

In the Ošťádal study, myocardial hypoxia resulted in a decline in mean (±SD) cardiac output to 2.3±1.2 L/min, systolic blood pressure to 61±7 mmHg and LV ejection fraction (EF) to 21±7 percent. Synchronized pulsatile flow was associated with significant reduction of LV end-systolic volume (ESV), increase in LV stroke volume (SV) and higher EF at all ECLS flow levels compared to continuous ECLS flow. At selected ECLS flow levels, pulsatile flow reduced also LV end-diastolic pressure (EDP), end-diastolic volume (EDV) and systolic pressure (SP).

Patients with cardiogenic shock have a very high mortality rate. It is a medical emergency which shock results from an inadequate circulation of blood due to primary failure of the heart ventricles to function effectively. As this is a type of circulatory shock, there is insufficient perfusion of tissue. The condition involves increasingly more pervasive cell death from oxygen starvation (hypoxia).

Synchronized cardiac assist overlays or superimposes a physiological pulse wave onto the patient’s weakened pulse. It is designed to be a less invasive treatment than the current standard while using a more physiological treatment designed to be essential to endothelial function, which ensures adequate tissue perfusion in the organs. Maintaining organ function serves to prevent multi-organ failure and to improve clinical outcomes. The energy of synchronized pulsatility in conjunction with the i-cor Synchronized Cardiac Assist device allows for a reduction of invasiveness compared to standard care by reducing blood flow and thus reducing cannula size. As a result, i-cor is designed to offer physiological cardiac assist, protection and safety during interventions in the cardiac cath lab, as well as for the management of cardiogenic shock in the ICU and the cardiac cath lab.

The i-cor device is cleared for sale in Europe but is not cleared for sale in the United States. 

For more information: www.xenios-ag.com

Related Content

Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init